What is Pandorum?
Pandorum Technologies operates at the intersection of biotechnology and advanced manufacturing, specializing in tissue engineering and regenerative medicine. The company utilizes a proprietary platform that integrates 3D bioprinting and cellular engineering to develop functional human tissues, including bio-engineered corneas, mini livers, and lung regeneration therapies. By providing these sophisticated biological models, Pandorum serves a critical need in medical research, drug discovery, and therapeutic development. Their market position is defined by a commitment to high-precision science, aiming to address complex medical conditions while adhering to stringent safety and quality standards. As a key player in the biotech ecosystem, Pandorum bridges the gap between laboratory innovation and clinical application, targeting healthcare organizations and research institutions globally.
How much funding has Pandorum raised?
Pandorum has raised a total of $29M across 2 funding rounds:
Other Financing Round
$11M
Series B
$18M
Other Financing Round (2024): $11M with participation from Indian Angel Network
Series B (2026): $18M led by Galentic Pharma Pvt and Avinya Ventures
Key Investors in Pandorum
Indian Angel Network
Indian Angel Network is a prominent network of angel investors focused on early-stage businesses with high growth potential, providing both capital and strategic mentorship.
Galentic Pharma Pvt
Galentic Pharma is a specialized manufacturer of sterile ophthalmic and dermatological products, bringing deep industry expertise and manufacturing standards to the investment.
Avinya Ventures
Avinya Ventures is a SEBI-approved early-stage venture capital fund that supports innovative startups across various sectors, including healthcare, through personalized support and global networking.
What's next for Pandorum?
With the recent influx of capital, Pandorum is poised to scale its operational capacity and expand its therapeutic pipeline. The strategic focus will likely shift toward optimizing its 3D printing infrastructure and advancing its bio-engineered tissue products through rigorous clinical validation phases. By fostering partnerships with healthcare providers and research entities, the company aims to transition its innovative therapies from experimental models to viable clinical solutions. This phase of growth is critical for Pandorum as it seeks to establish long-term sustainability and market leadership in the regenerative medicine landscape, ultimately aiming to transform patient outcomes through cutting-edge biotechnology.
See full Pandorum company page
